These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1635 related items for PubMed ID: 19942839

  • 1. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK, Castiglione-Gertsch M.
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [Abstract] [Full Text] [Related]

  • 2. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Rizzo P, Marino A, D'Amico M, Sponziello F, Mazzoni E, Cinefra M, Fazio N, Maiello E, Silvestris N, Colucci G, Cinieri S.
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [Abstract] [Full Text] [Related]

  • 3. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 4. Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.
    Baumann CK, Castiglione-Gertsch M.
    Drugs; 2007 Dec; 67(16):2335-53. PubMed ID: 17983255
    [Abstract] [Full Text] [Related]

  • 5. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ, Johnston SR, Howell A.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [Abstract] [Full Text] [Related]

  • 6. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF.
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [Abstract] [Full Text] [Related]

  • 7. Prevention of hormone-related cancers: breast cancer.
    Dunn BK, Wickerham DL, Ford LG.
    J Clin Oncol; 2005 Jan 10; 23(2):357-67. PubMed ID: 15637398
    [Abstract] [Full Text] [Related]

  • 8. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD, Wood ME, Muss HB.
    Oncology (Williston Park); 2004 Dec 10; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [Abstract] [Full Text] [Related]

  • 9. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S, Zelnak A, O'Regan R.
    Expert Rev Anticancer Ther; 2009 Feb 10; 9(2):187-98. PubMed ID: 19192957
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
    Dellapasqua S, Castiglione-Gertsch M.
    Breast; 2005 Dec 10; 14(6):555-63. PubMed ID: 16188442
    [Abstract] [Full Text] [Related]

  • 11. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV, Goldstein SR.
    Menopause; 2010 Dec 10; 17(3):642-53. PubMed ID: 20107426
    [Abstract] [Full Text] [Related]

  • 12. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A, Estévez LG, Lluch-Hernández A, Rodriguez-Lescure A, Rodriguez-Sanchez C, Sanchez-Rovira P.
    Adv Ther; 2011 Dec 10; 28(12):1045-58. PubMed ID: 22068628
    [Abstract] [Full Text] [Related]

  • 13. Focus on anastrozole and breast cancer.
    Mokbel K.
    Curr Med Res Opin; 2003 Dec 10; 19(8):683-8. PubMed ID: 14687437
    [Abstract] [Full Text] [Related]

  • 14. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR, Bartlett JM, Canney P, Verrill M.
    Breast Cancer Res Treat; 2007 Jun 10; 103(2):149-60. PubMed ID: 17039263
    [Abstract] [Full Text] [Related]

  • 15. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM.
    Oncology; 2006 Jun 10; 70(1):1-12. PubMed ID: 16439860
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS, Burstein HJ, Winer EP, Weeks JC.
    J Natl Cancer Inst; 2008 May 07; 100(9):642-8. PubMed ID: 18445827
    [Abstract] [Full Text] [Related]

  • 17. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK, Nielsen DL, Lindberg H, Kamby C.
    Ugeskr Laeger; 2007 Jan 22; 169(4):297-9. PubMed ID: 17274922
    [Abstract] [Full Text] [Related]

  • 18. [Treatment guideline for breast cancer and SERM-treatment].
    Iwase H, Yamamoto Y, Kawasoe T.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():636-40. PubMed ID: 18159717
    [No Abstract] [Full Text] [Related]

  • 19. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec 28; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 20. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
    Harwood KV.
    Clin J Oncol Nurs; 2004 Dec 28; 8(6):629-37. PubMed ID: 15637958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.